Skip to main content
. 2025 May 31;43(22):2502–2514. doi: 10.1200/JCO-25-00748

TABLE A1.

Postdiscontinuation Anticancer and Immunotherapy in All Treated Participants

Therapy Lenvatinib + Pembrolizumab + Chemotherapy (n = 443), No. (%) Chemotherapy (n = 437), No. (%)
Received any subsequent systemic anticancer therapy 202 (46) 273 (62)
Subsequent systemic therapy by type
 Chemotherapy 196 (44) 255 (58)
 Any PD-1/PD-L1 20 (5) 83 (19)
 Any VEGF 85 (19) 126 (29)
 Other 93 (21) 108 (25)
 Other immunotherapy 2 (1) 8 (2)

Abbreviation: VEGF, vascular endothelial growth factor.